The days of Roche having an immunotherapy monopoly on the largest population of small-cell lung cancer patients appear numbered, following the release of data for a competing drug.
If biopharma firms want to get the most out of continuous manufacturing, they must rethink their viral safety strategies. Existing strategies work well for batch-mode production, as hard-won experience attests. These strategies, however, are still being adapted to continuous-mode production, where protocols and equipment preferences are in flux.
By Dr. Kurt Newman, CEO of Children’s National Health System
We have come a long way in pediatric medicine, but not far enough.
For nearly a decade, the chief executives of the nation’s children’s hospitals and health systems have discussed challenges we face in caring for America’s very sickest children, whose life-threatening diseases and congenital conditions put overwhelming burdens on their families.
Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, and Catalent Biologics’ Paragon Gene Therapy unit, the leading viral vector development and manufacturing partner for gene therapies, today announced an arrangement under which Paragon Gene Therapy will assume the leases to two Novavax product development and manufacturing facilities, giving it immediate access to state-of-the-art manufacturing equipment, people and space to accelerate the growth of its gene therapy development and manufacturing business.
The University of Maryland School of Pharmacy has launched the nation’s first Master of Science program in medical cannabis science and therapeutics.
The university says the degree will provide students with the knowledge and skills needed to support patients and the medical cannabis industry.
As the dominant economic geography of America, metropolitan statistical areas largely determine our success as a nation. These groups of counties with a large central core account for 88.6 percent of jobs, 89.1 percent of wages and 90.0 percent of Gross Domestic Product (GDP). Further, metropolitan statistical areas account for the bulk of innovation such as research and development and patenting activity. Understanding the mechanisms underpinning the growth of top-performing metropolitan areas, and sharing best practices, could assist other communities in boosting their economic fortunes. The Most Dynamic Metropolitan Index, ranking 379 metropolitan areas, seeks to provide an objective measure of the economic vibrancy of communities where the lion’s share of Americans work and live.
Adaptive Biotechnologies has raised the price for its initial public offering, putting itself in a position to raise more cash than any other biotech IPO this year. The Seattle-based company, which makes technology that can read the genetic information of the human immune system, increased its target price to $18 to $19 per share and could raise as much as $327.5 million from investors, according to a new SEC filing.
Health Tech early stage (below $10 million) investing grew consistently from 2010 – 2017, but then stalled in 2018 showing declining deal count in every quarter over the previous year. At the same time, total capital invested was flat. Was it a correction?
Results from Q1 2019 show the segment is back on the growth track. Deal counts won’t yet match 2016 and 2017 levels, but they will be up from 2018 and capital invested in U.S. early stage health tech is likely to be the highest on record.
The company that makes Botox is the subject of the latest biopharma mega-deal.
Chicago-based AbbVie said Tuesday it would acquire Ireland-headquartered Allergan for $63 billion, or $78.45 per share, equal to the former’s Monday closing price. The companies said the deal would provide immediate scale and profitability for AbbVie while allowing the company to diversify into new therapeutic areas like aesthetics.
At the end of November in Washington, D.C., Children’s National Health System began work on a historical renovation construction project that will result in a pediatric research and innovation campus with a focus on pediatric medicine.